Bellevue, Washington Clinical Trials

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

A Phase 3b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Treatment Group, Multicenter Efficacy and Safety Study of Topical Diltiazem Hydrochloride 2% Cream in Subjects with Anal Fissure

Forest Investigative Site 040

Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder

Research Site

A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents

Northwest Clinical Research Center Updated

SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Northwest Clinical Research Center Updated

SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Research Site

Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation

Northwest Gastroenterology Associates Updated

26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation

Northwest Gastroenterology Associates

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Northwest Gastroenterology Associates

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment

Northwest Clinical Research Center

Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

Research Site

Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)

Research Site

A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder

Neurological Associates of Washington

Eslicarbazepine Acetate Monotherapy Long Term Study

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome

Overlake Medical Center

Longitudinal Surveillance Registry (LSR) of ACUITY Spiral

Nycomed Investigational Site

Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment in Vascular Surgery

Research Center

A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome

Research Site

Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)

Overlake Hospital Medical Center Updated

S0820, Adenoma and Second Primary Prevention Trial

Forest Investigative Site 066

Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain

Research Site

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

Northwest Clinical Research Center

Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Evacetrapib in High-Risk Vascular Disease